Challenges for blood–brain barrier (BBB) screening

References

• Abbott JN, Rönnbäck L, Hansson E. Astrocyte–endothelial interactions at the blood–brain barrier. Nature Reviews: Neuroscience 2006; 7: 41–53
   PubMed Web of Science ®Google Scholar
• Al-Awqati Q. One hundred years of membrane permeability: does Overton still rule?. Nature Cell Biology 1999; 1: E201–E202
   PubMed Web of Science ®Google Scholar
• Anthonypillai C, Sanderson RN, Gibbs JE, Thomas SA. The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig. Journal of Pharmacology and Experimental Therapy 2004; 308(3)912–920
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Netter P, Pourel J, Royer RJ, Gaucher A. Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs in the cerebrospinal fluid. Biomedicine and Pharmacotherapy 1989; 43(2)121–126
   PubMed Web of Science ®Google Scholar
• Becker S, Liu X. Evaluation of the utility of brain slice methods to study brain penetration. Drug Metabolism and Disposition 2006; 34: 855–861
   PubMed Web of Science ®Google Scholar
• Begley DJ, Brightman MW. Structural and functional aspects of the blood–brain barrier. Progress in Drug Research 2003; 61: 39–78
   PubMedGoogle Scholar
• Björklund A, Falck B, Hromek F, Owman C. An enzymic barrier mechanism for monoamine precursors in the newly-forming brain capillaries following electrolytic or mechanical lesions. Journal of Neurochemistry 1969; 16(12)1605–1608
   PubMed Web of Science ®Google Scholar
• Bonati M, Kanto J, Tognoni. Clinical pharmacokinetics of cerebrospinal fluid. Clinical Pharmacokinetics 1982; 7(4)312–335
   PubMed Web of Science ®Google Scholar
• Boström E, Simonsson US, Hammarlund-Udenaes M. In vivo blood–brain barrier transport of oxycodone in the rat: Indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metabolism and Disposition 2006; 34(9)1624–31
   PubMed Web of Science ®Google Scholar
• Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metabolism and Disposition 2003; 31(3)312–318
   PubMed Web of Science ®Google Scholar
• Chi CH, Dixit BN. Characterization of (±)-methadone uptake by rat lung. British Journal of Pharmacology 1977; 59(4)539–549
   PubMed Web of Science ®Google Scholar
• Chiou WL. New perspectives on the theory of permeability and resistance in the study of drug transport and absorption. Journal of Pharmacokinetics and Biopharmacology 1996; 24(4)433–442
   PubMedGoogle Scholar
• Clark DE. In silico prediction of blood–brain barrier permeation. Drug Discovery Today 2003; 8: 927–933
   PubMed Web of Science ®Google Scholar
• Cserr HF, Bundgaard M. Blood–brain interfaces in vertebrates: A comparative approach. American Journal of Physiology 1984; 246: R277–R288
   PubMed Web of Science ®Google Scholar
• Cucullo L, Aumayr B, Rapp E, Janigro D. Drug delivery and in vitro models of the blood–brain barrier. Current Opinions in Drug Discovery and Development 2005; 8(1)89–99
   PubMedGoogle Scholar
• De Boer AG, Gaillard PJ. Drug targeting to the brain. Annual Reviews in Pharmacology and Toxicology 2007; 47: 323–355
   PubMed Web of Science ®Google Scholar
• De Boer AG, Van der Sandt IC, Gaillard PJ. The role of drug transporters at the blood–brain barrier. Annual Reviews in Pharmacology and Toxicology 2003; 43: 629–656
   PubMed Web of Science ®Google Scholar
• De Lange ECM, Ravenstijn PGM, Groenendall D, Van Steeg TJ. Toward prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic–pharmacodynamic modelling. AAPS Journal 2005; 7(3)E532–E543
   PubMed Web of Science ®Google Scholar
• Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the mdr1a/b knockout mouse model. Drug Metabolism and Disposition 2005; 33: 165–174
   PubMed Web of Science ®Google Scholar
• Eytan GD, Kuchel PW. Mechanism of action of P-glycoprotein in relation to passive membrane permeation. International Reviews in Cytology 1999; 90: 175–250
   Google Scholar
• Feng MR. Assessment of blood–brain barrier penetration: in silico, in vitro, and in vivo. Current Drug Metabolism 2002; 3: 647–657
   PubMed Web of Science ®Google Scholar
• Fridén M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M. Drug Metabolism and Disposition. 2007, (in press)
   Google Scholar
• Goadsby PJ. The pharmacology of headache. Progress in Neurobiology 2000; 62(5)509–525
   PubMed Web of Science ®Google Scholar
• Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. Journal of Cerebral Blood Flow and Metabolism 2001; 21(6)635–652
   PubMed Web of Science ®Google Scholar
• Gupta A, Chatelain P, Massingham R, Jonsson EN, Hammarlund-Udenaes M. Brain distribution of cetirizine enantiomers: Comparison of three different tissue-to-plasma partition coefficients: K(p), K(p,u), and K(p,uu). Drug Metabolism and Disposition 2006; 34(2)318–323
   PubMed Web of Science ®Google Scholar
• Henthorn TK, Liu Y, Mahapatro M, Ng KY. Active transport of fentanyl by the blood-brain barrier. Journal of pharmacology and Experimental Therapeutics 1999; 289(2)1084–1089
   PubMed Web of Science ®Google Scholar
• Hitchcock SA, Pennington LD. Structure–brain exposure relationships. Journal of Medicine and Chemistry 2006; 49: 1–25
   PubMed Web of Science ®Google Scholar
• Höber R. Membrane permeability to solutes in its relations to cellular physiology. Physiology Review 1936; 16: 52
   Google Scholar
• Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, Kanai Y, Naito M, Tsuruo T, Minato N, et al. The 4F2hc/LAT1 complex transports L-DOPA across the blood–brain barrier. Brain Research 2000; 879(1–2)115–121
   PubMed Web of Science ®Google Scholar
• Kalvass JC, Maurer TS. Influence of non-specific brain and plasma binding on CNS exposure: Implications for rational drug discovery. Biopharmacology and Drug Disposition 2002; 23: 327–338
   PubMed Web of Science ®Google Scholar
• Kalvass JC, Maurer TS, Pollack GM. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: Comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios. Drug Metabolism and Disposition 2007; 35: 660–666
   PubMed Web of Science ®Google Scholar
• Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, Yokoi T. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. Journal of Pharmacy Science 2006; 95(12)2673–2683
   PubMed Web of Science ®Google Scholar
• Katritzky AR, Kuanar M, Slavov S, Dobchev DA, Fara DC, Karelson M, Acree WE, Solov’ev VP, Varnek A. Correlation of blood–brain penetration using structural descriptors. Bioorganic and Medicinal Chemistry 2006; 14(14)4888–4917
   PubMed Web of Science ®Google Scholar
• Kepner GR. In Cell membrane permeability and transport. Dowden, Hutchins & Ross, Stroudsberg, PA 1979; 29–56
   Google Scholar
• Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharmacy Research (New York) 2000; 17: 1456–1460
   PubMed Web of Science ®Google Scholar
• Lin JH. How significant is the role of P-glycoprotein in drug absorption and brain uptake?. Drugs of Today 2004; 40(1)5–22
   PubMed Web of Science ®Google Scholar
• Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, et al. Use of a physiologically based pharmacokinetics model to study the time to reach brain equilibrium: An experimental analysis if the role of blood–brain barrier permeability, plasma protein binding, and brain tissue binding. Journal of Pharmacology and Experimental Therapy 2006; 313: 1254–1262
   Web of Science ®Google Scholar
• Loscher W, Frey HH. Kinetics of penetration of common antiepileptic drugs into cerebrospinal fluid. Epilepsia 1984; 25(3)346–352
   PubMed Web of Science ®Google Scholar
• Luer MS, Hamani C, Dujovny M, Gidal B, Cwik M, Deyo K, Fischer JH. Saturable transport of gabapentin at the blood–brain barrier. Neurology Research 1999; 21(6)559–562
   PubMed Web of Science ®Google Scholar
• Lundquit S, Renftel M, Brillault J, Fenart L, Cecchelli R, Dehouck MP. Prediction of drug transport through the blood-brain barrier in vivo: A comparison between two in vitro cell models. Pharmaceutical Research 2002; 19: 976–981
   PubMed Web of Science ®Google Scholar
• Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. Journal of Pharmacology and Experimental Therapy 2002; 303(3)1029–1037
   PubMed Web of Science ®Google Scholar
• Mahar Doan KM, Wring SA, Shampine LJ, Jordan KH, Bishop JP, Kratz J, Yang E, Serabjit-Singh CJ, Adkison KK, Polli JW. Steady-state brain concentrations of antihistaminer in rats: interplay of membrane permeability, p-glycoprotein efflux and plasma protein binding. Pharmacology 2004; 72(2)92–98
   PubMed Web of Science ®Google Scholar
• Martin I. Prediction of blood–brain barrier penetration: are we missing the point. Drug Discovery Today 2004; 9(4)161–162
   PubMed Web of Science ®Google Scholar
• Maurer TS, Debartolo DB, Tess DA, Scott DO. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metabolism and Disposition 2005; 33: 175–181
   PubMed Web of Science ®Google Scholar
• Mayer S, Maickel RP, Brodie BB. Kinetics of penetration of drugs and other foreign compounds into cerebrospinal fluid and brain. Journal of Pharmacology and Experimental Therapy 1959; 127(3)205–211
   Web of Science ®Google Scholar
• Meresse S, Dehouck MP, Delorme P, Bensaid M, Tauber JP, Delbart C, Fruchart JC, Cecchelli R. Bovine brain endothelial cells express tight junctions and monoamine oxidase activity in long-term culture. Journal of Neurochemistry 1989; 53(5)1363–1371
   PubMed Web of Science ®Google Scholar
• Meyer RP, Gehlhaus M, Knoth R, Volk B. Expression and function of cytochrome p450 in brain drug metabolism. Current Drug Metabolism 2007; 8(4)297–306
   PubMed Web of Science ®Google Scholar
• Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacology Reviews 2003; 55(3)425–461
   PubMed Web of Science ®Google Scholar
• Moriki Y, Suzuki T, Furuishi T, Fukami T, Tomono K, Watanabe J. In vivo evidence for the efflux transport of pentazocine from the brain across the blood–brain barrier using the brain efflux index method. Journal of Drug Target 2005; 13(1)53–59
   PubMed Web of Science ®Google Scholar
• Narayanan R, Gunturi SB. In silico ADME modelling: prediction models for blood–brain permeation using a systemic variable selection method. Bioorganic and Medicinal Chemistry 2005; 13: 3017–3028
   PubMed Web of Science ®Google Scholar
• Naruhashi K, Tamai I, Li Q, Sai Y, Tsuji A. Experimental demonstration of the unstirred water layer effect on drug transport in Caco-2 cells. Journal of Pharmacy Science 2003; 92(7)1502–1508
   PubMed Web of Science ®Google Scholar
• Norinder U, Haeberlin M. Computational approaches to the prediction of the blood–brain distribution. Advanced Drug Delivery Reviews 2002; 54: 291–313
   PubMed Web of Science ®Google Scholar
• Ohe T, Sato M, Tanaka S, Fujino N, Hata M, Shibata Y, Kanatani A, Fukami M, Yamakazi M, Chiba M, et al. Effect of P-glycoprotein mediated efflux on cerebrospinal fluid/plasma concentration ratio. Drug Metabolism and Disposition 2003; 31: 1251–1254
   PubMed Web of Science ®Google Scholar
• Overton E. Vierteljahrsschr. Naturforsch. Ges. Zurich 1899; 44: 88–135
   Google Scholar
• Pardridge WM. Blood–brain barrier delivery. Drug Discovery Today 2007; 12(1–2)54–61
   PubMed Web of Science ®Google Scholar
• Parepally JM, Mandula H, Smith QR. Brain uptake of nonsteroidal anti-inflammatory drugs: Ibuprofen, Flurbiprofen, and Indomethacin. Pharmacology Research 2006; 23(5)873–881
   PubMed Web of Science ®Google Scholar
• Polli JW, Humphreys JE, Wring SA, Burnette TC, Read KD, Hersey A, Butina D, Bertolotti L, Pugnaghi F, Serabjit-Singh C. A comparison of Madin–Darby canine kidney cells and bovine brain endothelial cells as a blood–brain barrier screen in early drug discovery. Progress in the reduction, refinement and replacement of animal experimentation, M Balls, AM Van Zeller, ME Halder. Elsevier, Amterdam 2000; 271–289
   Google Scholar
• Reichal A. The role of blood–brain barrier studies in the pharmaceutical industry. Current Drug Metabolism 2006; 7: 183–203
   PubMed Web of Science ®Google Scholar
• Sieppman J, Siepmann F, Florence AT. Local controlled drug delivery to the brain: Mathematical modelling of the underlying mass transport mechanisms. International Journal of Pharmaceutics 2006; 314: 101–119
   PubMed Web of Science ®Google Scholar
• Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science 1972; 175(23)720–731
   PubMed Web of Science ®Google Scholar
• Snyder WS, Cook MJ, Nasset ES, Karhausen LR, Howells GP, Tipton IH. Report of the Task Force on Reference Man. Pergamon, Oxford 1975
   Google Scholar
• Su Y, Zhang X, Sinko PJ. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Molecular Pharmacology 2004; 1(1)49–56
   Web of Science ®Google Scholar
• Summerfield SG, Jeffrey P. In vitro prediction of brain penetration–a case for free thinking?. Expert Opinions in Drug Discovery 2006a; 1(6)595–607
   PubMed Web of Science ®Google Scholar
• Summerfield SG, Read KD, Begley, Obradovic TT, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P. CNS drug disposition: The relationship between in situ brain permeability and brain free fraction. Journal of Pharmacology and Experimental Therapy 2007; 322: 205–213
   PubMed Web of Science ®Google Scholar
• Summerfield SG, Stevens AJ, Cutler L, Del Carmen Osuna M, Hammond B, Tang SP, Hersey A, Spalding DJ, Jeffrey P. Improving the in vitro prediction of in vivo central nervous system penetration: Integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. Journal of Pharmacology and Experimental Therapy 2006b; 316: 1282–1290
   PubMed Web of Science ®Google Scholar
• Sun JJ, Xie L, Liu XD. Transport of carbamazopine and drug interactions at blood-brain barrier. Acta Pharmacologica scnica. 2006; 27(2)244–253
   Web of Science ®Google Scholar
• Sung JH, Yu KH, Park JS, Tsuruo T, Kim DD, Shim CK, Chung SJ. Saturable distribution of tacrine into the striatal extracellular fluid of the rat: Evidence of involvement of multiple organic cation transporters in the transport. Drug Metabolism and Disposition 2005; 33(3)440–448
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Yoshitomi S, Higuchi T, Ikemoto K, Niwa S, Ebihara T, Katoh M, Yokoi T, Asahi S. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharmacology Research 2006; 23(7)1460–1472
   PubMed Web of Science ®Google Scholar
• Tran TT, Mittal A, Gales T, Maleeff B, Aldinger T, Polli JW, Ayrton A, Ellens H, Bentz J. Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. Journal of Pharmacy Science 2004; 93(8)2108–2123
   PubMed Web of Science ®Google Scholar
• Uchino H, Kanai Y, Kim do K, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H. Transport of amino acid-related compounds mediated by L-type amino acid transporter (LAT1): Insights into the mechanisms of substrate recognition. Molecular Pharmacology 2002; 61: 729–737
   PubMed Web of Science ®Google Scholar
• US Food and Drug Agency (USFDA). Drug interaction studies–study design, data analysis and implications for dosing and labelling. Draft Guidance for Industry. USFDA, Rockville, MD September, 2006, (2006), available at: )
   Google Scholar
• Van Breemen RB, Li Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opinion on Drug Metabolism and Toxicology 2005; 1(2)175–185
   PubMedGoogle Scholar
• Van de Waterbeemd H, Smith DA, Jones BC. Lipophilicity in PK design: Methyl, ethyl, futile. Journal of Computer-Aided Molecular Design 2001; 15(3)273–286
   PubMed Web of Science ®Google Scholar
• Wang Q, Rager JD, Weinstein K, Kardos P, Dobson GL, Li J, Hidalgo IJ. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood–brain barrier. International Journal of Pharmacology 2005; 288: 349–359
   PubMed Web of Science ®Google Scholar